

**Annex D – Post-Class Period Exhibits Challenged in Opposition**

Exhibit No.	Description	Cited in MTD	Bases for Court's Consideration
56	Press Release – “AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization” (Feb. 15, 2021)	Pgs. 4, 13, 21, 25	<ul style="list-style-type: none"> <li>• Cited for WHO approval of AZD1222 for those aged 18+, which is judicially noticeable, undisputed, and acknowledged in the Opp. at nn.20, 37</li> <li>• Cited for AZ’s stated commitment to equitable distribution and no-profit from AZD1222 during pandemic, which is undisputed and acknowledged in the AC, ¶¶ 36, 38, 47, 60, 61, and Opp. at 3-4 &amp; n.5</li> </ul>
58	“Germany Approves AstraZeneca for over-65s, extends gap between doses,” <i>Reuters</i> (Mar. 4, 2021)	Pgs. 21, 34	<ul style="list-style-type: none"> <li>• Cited for German regulators’ approval of AZD1222 for those aged 65+, which is judicially noticeable, undisputed, and acknowledged in the Opp. at nn.20, 37</li> </ul>
60	Press Release – “Update following statement by NIAID on AZD1222 US Phase III trial data” (Mar. 23, 2021)	Pg. 14	<ul style="list-style-type: none"> <li>• Cited for DSMB response to AZD1222 trial data, which is judicially noticeable, undisputed, and referenced in the AC, ¶¶ 129-130</li> </ul>
62	AstraZeneca PLC (AZN) CEO Pascal Soriot on Q2 2021 Results – Earnings Call Transcript (Aug. 1, 2021)	Pgs. 4, 14, 25	<ul style="list-style-type: none"> <li>• Cited for AZ’s stated commitment to equitable distribution of AZD1222, which is undisputed and acknowledged in the AC, ¶¶ 38, 47, 60, 61 and Opp. at n.5</li> </ul>
63	Press Release – “Oxford vaccine reaches one billion doses released” (July 29, 2021)	Pgs. 14, 31	<ul style="list-style-type: none"> <li>• Cited for number of AZD1222 doses released, which is undisputed and acknowledged in the Opp at nn.20, 37</li> <li>• Cited for AZ’s stated commitment to equitable distribution, which is undisputed and acknowledged in the AC, ¶¶ 38, 47, 60, 61, and Opp. at n.5</li> </ul>
64	Pascal Soriot Bloomberg Interview Transcript (July 29, 2021)	Pg. 14	<ul style="list-style-type: none"> <li>• Cited for recognition that three COVID-19 vaccines had already received FDA EUA approval, which is judicially noticeable, undisputed, and acknowledged in the Opp. at 2 &amp; n.20</li> </ul>

Exhibit No.	Description	Cited in MTD	Bases for Court's Consideration
			<ul style="list-style-type: none"> <li>• Cited for AZ's disclosure that it would not seek FDA EUA and would instead seek full regulatory approval, which is undisputed and acknowledged in the Opp. at Ex. A</li> </ul>
65	"AstraZeneca coronavirus vaccine sales triple, but US plans delayed again," <i>The National</i> (July 29, 2021)	Pg. 14	<ul style="list-style-type: none"> <li>• Cited for recognition that three COVID-19 vaccines had already received FDA EUA approval, which is judicially noticeable, undisputed, and acknowledged in the Opp. at 2 &amp; n.20</li> <li>• Cited for AZ's disclosure that it would not seek FDA EUA and would instead seek full regulatory approval, which is undisputed and acknowledged in the Opp. at Ex. A</li> </ul>
66	FDA News Release – "FDA Approves First Covid-19 Vaccine" (Aug. 23, 2021)	Pg. 14	<ul style="list-style-type: none"> <li>• Cited for FDA approval of Pfizer-BioNTech COVID-19 vaccine, which is judicially noticeable and undisputed</li> </ul>
67	"Tracking Coronavirus Vaccinations Around the World," <i>The New York Times</i> (as of Sept. 27, 2021)	Pg. 14	<ul style="list-style-type: none"> <li>• Cited for use of AZD1222 globally, which is judicially noticeable, undisputed, and acknowledged in the Opp. at nn.20, 37</li> </ul>